C

Concord Biotech Ltd
NSE:CONCORDBIO

Watchlist Manager
Concord Biotech Ltd
NSE:CONCORDBIO
Watchlist
Price: 2 151.05 INR 0.71% Market Closed
Market Cap: 225B INR
Have any thoughts about
Concord Biotech Ltd?
Write Note

Concord Biotech Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Concord Biotech Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
C
Concord Biotech Ltd
NSE:CONCORDBIO
Current Portion of Long-Term Debt
â‚ą78.5m
CAGR 3-Years
-33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Current Portion of Long-Term Debt
â‚ą41.2B
CAGR 3-Years
256%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Current Portion of Long-Term Debt
â‚ą2.4B
CAGR 3-Years
48%
CAGR 5-Years
N/A
CAGR 10-Years
-17%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Current Portion of Long-Term Debt
â‚ą22B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Current Portion of Long-Term Debt
â‚ą16.5B
CAGR 3-Years
-6%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Current Portion of Long-Term Debt
â‚ą231.2m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Concord Biotech Ltd
Glance View

Market Cap
225B INR
Industry
Pharmaceuticals

Nestled in the vibrant landscape of the Indian pharmaceutical industry, Concord Biotech Ltd. has woven itself into the intricate fabric of global healthcare solutions. Founded in 2000, the company has carved a niche for itself by becoming a leading manufacturer of fermentation-based biopharmaceutical APIs (Active Pharmaceutical Ingredients). Its core strength lies in developing recombinant APIs and fermentation-based life-saving drugs, establishing a robust pipeline that caters to the therapeutic needs of oncology, immunology, and infectious diseases. Concord Biotech's state-of-the-art manufacturing facilities adhere to stringent international standards, including approvals from USFDA and EUGMP, enabling the company to establish a significant presence in markets across the globe. The company's revenue model thrives on the optimized production of high-demand biotech APIs, synergizing innovation with commercial viability. By partnering with global pharmaceutical giants, Concord Biotech boosts the formulation and development of finished dosage forms, leveraging its cutting-edge research and development capabilities. The firm taps into economies of scale via partnerships and strategic alliances, which allow it to competitively price its offerings while maintaining robust profit margins. Moreover, the company continually invests in expanding its product portfolio and production capacities, ensuring sustainable growth and a strong market position in the ever-evolving pharmaceutical landscape. Through a combination of technological prowess and market insight, Concord Biotech Ltd. paves its path as a cornerstone in the global pharmaceutical supply chain.

CONCORDBIO Intrinsic Value
1 126.37 INR
Overvaluation 48%
Intrinsic Value
Price
C

See Also

What is Concord Biotech Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
78.5m INR

Based on the financial report for Mar 31, 2024, Concord Biotech Ltd's Current Portion of Long-Term Debt amounts to 78.5m INR.

What is Concord Biotech Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
-33%

Over the last year, the Current Portion of Long-Term Debt growth was -69%. The average annual Current Portion of Long-Term Debt growth rates for Concord Biotech Ltd have been -33% over the past three years .

Back to Top